doi: 10.4161/21623945.2014.983752 58 NauckMAQuastDRWefersJMeierJJ
Retatrutide, a much-hyped injection that is in the works, can apparently lead to nearly 30 percent loss in body weight on average
Clinical trials (such as SUSTAIN-6) have shown cardiovascular benefits in people with type 2 diabetes taking semaglutide, though it does not have a specific UK indication for cardiovascular risk reduction
Table 3 Results of a 52-week Monotherapy Trial in Adults with Type 2 Diabetes Mellitus a Figure 3 Mean HbA 1c for Adult Patients with Type 2 Diabetes Mellitus who Completed the 52-week Trial and for the Last Observation Carried Forward (LOCF, intent-to-treat) data at Week 52 (Monotherapy) Combination Therapy Add-on to Metformin In this 26-week trial, 1,091 adult patients with type 2 diabetes mellitus were randomized to liraglutide injection 0.6 mg, liraglutide injection 1.2 mg, liraglutide injection 1.8 mg, placebo, or glimepiride 4 mg (one-half of the maximal approved dose in the United States), all as add-on to metformin
The Mayo Clinic Healthy Weight Pyramid is divided into three sections that provide guidance on food and lifestyle choices